Roche announced positive results for three pivotal Phase III studies of experimental MS therapy ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis (PPMS) patients at this year’s ECTRIMS 2015 conference. The results, particularly for treating PPMS, indicate that the novel therapy may represent…
Ocrevus
Genentech, a leading biotechnology company and member of the Roche Group, recently announced promising results on a pivotal Phase III clinical trial (ORATORIO) assessing its investigational therapy ocrelizumab as a treatment for patients with primary progressive multiple sclerosis (PPMS). Multiple sclerosis (MS) is a chronic, progressive neurodegenerative disorder that results from…
On September 16, 2015, Swiss pharmaceutical company Roche announced that ocrelizumab, a drug originally designed to treat rheumatoid arthritis that saw its development stopped due to an association with infections, could potentially treat relapsing-remitting multiple sclerosis (RRMS) as well as primary progressive MS (PPMS) with minimal sides effects compared…
Pharmaceutical giant Novartis recently announced it has signed an agreement with GlaxoSmithKline for exclusive rights to GSK’s investigational CD20-specific monoclonal antibody, Ofatumumab, indicated for relapsing remitting multiple sclerosis (RRMS) and other autoimmune diseases. Novartis had previously acquired rights to the drug for its indications in oncology, effectively marketing it under brand name Arzerra®.
Roche recently announced encouraging results on its investigational medicine ocrelizumab as a therapy for patients with relapsing multiple sclerosis, which includes either RRMS or SPMS with relapses. Ocrelizumab was evaluated in two pivotal studies (OPERA I and OPERA II), where it was compared to interferon (IFN) beta-1a (Rebif®), the standard-of-care…